Aim: Human carbonic anhydrase (CA, EC 4.2.1.1) isoforms IX and XII are validated anti-tumor/antimetastatic drug and tumor imaging targets with sulfonamide inhibitors and monoclonal antibodies in clinical development. Coumarins act as isoform-selective inhibitors of these isoforms over the cytosolic and mitochondrial ones. Methods: We report the synthesis and in vitro CA inhibitory evaluation of a large panel of coumarins incorporating pyrazole-1-carboxamide moieties. Compounds were fully characterized before the assessment of their inhibitory activi-ty. A stopped-flow CO2 hydrase assay was performed for the biological test. Results: These coumarins did not inhibit the widespread, off-target isoforms CA I and II (KI >50 μM), but they were sub-micromolar CA IX/XII inhibitors with an interesting selectivity index higher than the reference compound. Selectivity between α-and β-class of CAs was also promising. Conclusion: These compounds may be used as leads for the rational design and development of non-sulfonamide CA IX/XII effective inhibitors.

Coumarin-pyrazoline Hybrids as Selective Inhibitors of the Tumor-associated Carbonic Anhydrase IX and XII

Carradori S.
Secondo
;
2023-01-01

Abstract

Aim: Human carbonic anhydrase (CA, EC 4.2.1.1) isoforms IX and XII are validated anti-tumor/antimetastatic drug and tumor imaging targets with sulfonamide inhibitors and monoclonal antibodies in clinical development. Coumarins act as isoform-selective inhibitors of these isoforms over the cytosolic and mitochondrial ones. Methods: We report the synthesis and in vitro CA inhibitory evaluation of a large panel of coumarins incorporating pyrazole-1-carboxamide moieties. Compounds were fully characterized before the assessment of their inhibitory activi-ty. A stopped-flow CO2 hydrase assay was performed for the biological test. Results: These coumarins did not inhibit the widespread, off-target isoforms CA I and II (KI >50 μM), but they were sub-micromolar CA IX/XII inhibitors with an interesting selectivity index higher than the reference compound. Selectivity between α-and β-class of CAs was also promising. Conclusion: These compounds may be used as leads for the rational design and development of non-sulfonamide CA IX/XII effective inhibitors.
File in questo prodotto:
File Dimensione Formato  
manuscript Toraskar 2023.pdf

Solo gestori archivio

Tipologia: PDF editoriale
Dimensione 815.55 kB
Formato Adobe PDF
815.55 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/808671
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact